Watch BOLT. Know when insiders buy.
One email the day a filing lands. Free.
BOLT
Bolt Biotherapeutics, Inc.
3.86
−0.04 −1.03%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $7.4MP/E —DIV YIELD —FCF YIELD —REV TTM $4.7M +12.8%NET INCOME −$28.7MNET CASH —52W 3.18 – 7.09SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $5K | −99.7% | — | −$8.4M | −$7.7M | — | -4.57 | −$6.5M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | $26K | −97.9% | — | −$7.6M | −$7.2M | — | -4.31 | −$8M | — | — | May 12 |
| Q4 2025 · Dec 31derived | $2.5M | — | — | −$7.1M | −$6.6M | — | -3.91 | −$7.2M | $0 | −$7.2M | Mar 12 |
| Q3 2025 · Sep 30 | $2.2M | +90.1% | — | −$7.7M | −$7.1M | — | -3.72 | −$9.7M | $72K | −$9.8M | Nov 12 |
| Q2 2025 · Jun 30 | $1.8M | +41.5% | — | −$9.2M | −$8.6M | — | -4.46 | −$9.6M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | $1.2M | −76.8% | — | −$12.1M | −$11M | — | -5.76 | −$13.4M | — | — | May 12 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$16.9M | −$15.9M | — | -8.33 | −$14.4M | $0 | −$14.4M | Mar 12 |
| Q3 2024 · Sep 30 | $1.1M | −54.9% | — | −$16.4M | −$15.2M | — | -7.93 | −$14M | $41K | −$14M | Nov 12 |
| Q2 2024 · Jun 30 | $1.3M | — | — | −$22.6M | −$21.2M | — | -11.12 | −$16.1M | $0 | −$16.1M | Aug 14 |
| Q1 2024 · Mar 31 | $5.3M | — | — | −$17.1M | −$10.8M | — | -0.28 | −$16.8M | $0 | −$16.8M | May 12 |
| Q4 2023 · Dec 31derived | $2.1M | — | — | −$19.8M | −$17.9M | — | -0.47 | −$14.3M | $6K | −$14.3M | Mar 24 |
| Q3 2023 · Sep 30 | $2.5M | — | — | −$18.2M | −$16.3M | — | -0.43 | −$16.7M | $165K | −$16.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $7.7M | — | −$36.1M | −$33.4M | -433.7% | -17.85 | −$39.9M | $72K | −$39.9M | — | — |
| FY2024 · to Dec 31 | $7.7M | — | −$73M | −$63.1M | -820.8% | -33.06 | −$61.3M | $41K | −$61.3M | — | — |
| FY2023 · to Dec 31 | $7.9M | — | −$76.2M | −$69.2M | -878.6% | -1.83 | −$69.5M | $206K | −$69.7M | — | — |
| FY2022 · to Dec 31 | $5.7M | — | −$90.3M | −$88.1M | -1537.8% | -2.36 | −$76.5M | $2M | −$78.5M | — | — |
| FY2021 · to Dec 31 | $1.3M | — | −$92.8M | −$98.6M | -7824.7% | -2.97 | −$57.1M | $2.3M | −$59.4M | — | — |
| FY2020 · to Dec 31 | $231K | — | −$49.2M | −$60.7M | -26289.2% | -28.89 | −$47.3M | $3.3M | −$50.6M | — | — |
Every number comes from Bolt Biotherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.